Summit Therapeutics plc - Company & Market Research Reports

Summit Therapeutics is a biopharmaceutical company focussed on the development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile. The company is developing Ezutromid, an utrophin modulator product candidate that is in Phase II clinical trials used for to treat Duchenne muscular dystrophy disease. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.